Home Infusion of COVID-19 Monoclonal Antibodies

NHIA is working with the Department of Health and Human Services (HHS) to increase access to bamlanivimab (Eli Lilly) for COVID-19 in high-risk, eligible individuals residing or working in long-term care facilities, including assisted living facilities. The program utilizes home infusion providers – in partnership with facility staff – to identify, assess, coordinate, dispense, and administer monoclonal antibody therapies in these healthcare settings. 

Through this pilot, NHIA is part of HHS’ Special Projects for Equitable and Efficient Distribution (SPEED) program.

Home infusion providers who wish to participate in the program and meet the eligibility criteria will be listed on a publicly accessible database for states to reference for future COVID-19 treatment opportunities.

The program is open to both NHIA member and non-member provider organizations, provided they qualify. In order to participate, a provider must:

  • Be a licensed pharmacy in good standing
  • Be accredited in home infusion
  • Be enrolled with the Centers for Medicare and Medicaid Services (CMS) as a pharmacy or vaccine/immunization provider
  • Be able to perform patient assessments for eligibility per the Emergency Use Authorization, obtain physician orders, coordinate nursing services for administration, dispense, and deliver the product
  • Make every effort to perform infusions within 24 hours of receiving a qualified referral
  • Be able to collect and submit required data

To enroll in the pilot, home infusion providers will need to fill out an online application, sign a participation agreement, and return via email to

To access the full list of questions needed to complete the program application prior to filling it out, click below.
It is recommended to do this before proceeding with the application.


NHIA recently partnered with the Department of Health and Human Services (HHS) to launch our Bamlanivimab Pilot Program, to facilitate the administration of bamlanivimab in long-term care facilities. This program is part of HHS’s Special Projects for Equitable and Efficient Distribution (SPEED). Learn more about the program, patient demographics, costs, clinical outcomes, and more. Access the report now.

NHIA HHS Bamlanivimab Pilot Provider List

Hear from the NHIA team about the new NHIA Bamlanivimab Pilot Program, with information about the program and applicant requirements 
on this on-demand webinar.

Pilot Program Office Hours

Bamlanivimab Pilot Program Office Hours NHIA will host weekly office hours to answer questions about the newly launched Bamlanivimab Pilot Program. These calls will provide an opportunity for home infusion providers, facility staff, and other stakeholders to learn more about the program framework and goals. Sessions will be held weekly on Fridays at 10 a.m. Eastern Time. Relevant updates will be shared, and participants will be able to ask NHIA team members questions about the program.

The registration link below will sign you up for the series of office hours through the end of February – attending all sessions is not required.

HHS/ASPR COVID-19 OUtpatient therapeutics

Starts December 9, 2020
This mini-series will provide a deep dive on new and emerging COVID-19 outpatient therapeutics, including monoclonal antibodies.
The goal of this mini-series is to equip clinicians with the appropriate knowledge, resources, and tools needed to initiate and scale administration of these therapies and reduce strain on the U.S. healthcare system.

Monoclonal Antibody Resources for COVID-19

COVID-19 Vaccines and Monoclonal Antibody Infusion: Enforcement Discretion Relating to SNF Consolidated Billing

To facilitate the efficient administration of COVID-19 vaccines to Skilled Nursing Facility (SNF) residents, CMS is exercising enforcement discretion with respect to statutory provisions requiring consolidated billing by SNFs as well as any associated statutory references and implementing regulations, including as interpreted in pertinent guidance. Through the exercise of this discretion, we will allow Medicare-enrolled immunizers working within their scope of practice and subject to applicable state law, including, but not limited to, pharmacies working with the United States, as well as infusion centers, and home health agencies, to bill directly and receive direct reimbursement from the Medicare program for vaccinating Medicare Part A SNF residents. This enforcement discretion, and accordingly the ability for entities other than the SNF to submit claims for these monoclonal antibody products and their administration furnished to Medicare Part A SNF residents, is limited to the period described in the above-cited enforcement discretion notice.